Last updated: April 3, 2026
What is NDC 33342-0132?
NDC 33342-0132 refers to a specific drug identified by the National Drug Code (NDC) number. Based on publicly available databases and the FDA's NDC directory, this NDC corresponds to Eravacycline (brand: Xerava), an antibiotic used primarily for complicated intra-abdominal infections (cIAI).
Market Size and Demand Drivers
Current Market Scope
Eravacycline was approved by the FDA in August 2018. The antibiotic addresses unmet needs in hospital settings, especially against multidrug-resistant organisms.
- Market Penetration: As of 2023, Eravacycline is available through specialized hospital formularies, primarily in the United States.
- Market Penetration Rate: Estimated around 15-20% in hospitals treating cIAI, with potential for growth given the rising resistance concern.
Key Demand Factors
- Antimicrobial Resistance (AMR): Increasing resistance to carbapenems and other broad-spectrum antibiotics drives demand for alternative agents like Eravacycline.
- Regulatory Renewals: The FDA's approval and updates, including label expansions or new indications, influence adoption.
- Hospital Protocols: Adoption depends on hospital antimicrobial stewardship programs and formulary decisions.
Competitive Landscape
- Main Competitors: Tigecycline (Tygacil), carbapenems, cephalosporins.
- Differentiation: Eravacycline has broad-spectrum activity, including resistant gram-negative bacteria, with fewer side effects compared to similar drugs.
Pricing Structures and Trends
Current Pricing Data
- Average Wholesale Price (AWP): Approximately $2,200 - $2,600 per IV dose (per vial) as of 2023.
- Annual Treatment Cost: For a typical course (7-14 days), total costs range from $15,400 to $36,400 depending on dosing and institutional discounts.
Pricing Comparison
| Parameter |
Eravacycline (Xerava) |
Tigecycline (Tygacil) |
Meropenem (Merrem) |
| Average cost per dose |
~$2,400 |
~$2,200 |
~$170 |
| Treatment duration |
7-14 days |
7-14 days |
7-14 days |
| Total treatment cost |
$15,400 - $36,400 |
$15,400 - $30,800 |
$1,200 - $2,400 |
Pricing Trends
- Recent Market Movements: Slight increases in list prices have been observed as demand for resistant infection management rises.
- Insurance/Contract Negotiations: Hospitals and pharmacy benefit managers (PBMs) negotiate discounts, lowering actual acquisition costs.
Price Projections
Short-term (Next 1-2 years)
- Prices are expected to stabilize owing to limited competition within its niche.
- Slight increases of 2-3% annually are probable, driven by inflation and supply chain factors.
- Market expansion into outpatient settings remains limited but could influence pricing if approved for additional indications.
Long-term (3-5 years)
- With more antibiotic resistance and potential formulation or indication expansions, prices could rise by 5-7% annually.
- Competition from generics or biosimilars is unlikely soon; the drug is still under patent exclusivity.
Potential for Price Decline
- Introduction of biosimilar or generic competitors could reduce prices by 20-30% within 5 years.
- Policy changes, such as increased formulary restrictions or price regulation, could impact margins.
Regulatory and Market Policy Impact
- Price adjustments linked to government health policies could influence costs.
- Medicaid/Medicare negotiations may further drive down net prices.
Summary of Key Assumptions and Risks
| Assumption |
Risk |
| Continued resistance trends elevate demand |
Emergence of new antibiotics reducing reliance |
| Stable hospital formulary adoption |
Regulatory delays or restrictions on use |
| No immediate generic competition |
Faster-than-expected patent expiries |
Key Takeaways
- NDC 33342-0132 (Eravacycline) serves a niche market for resistant intra-abdominal infections.
- Current prices hover around $2,200 to $2,600 per vial, translating to $15,400–$36,400 per course.
- Market demand is driven by rising antimicrobial resistance, with moderate growth expectations.
- Prices are expected to grow modestly (2-7%) annually over the next 2-5 years assuming no significant competitive entry.
- Long-term pricing outlook depends on resistance trends, formulary adoption, and potential biosimilars or generics.
FAQs
1. What are the main clinical indications for NDC 33342-0132?
Treatment of complicated intra-abdominal infections in adult patients.
2. How does the price of Eravacycline compare to other antibiotics?
It is significantly higher than broad-spectrum agents like meropenem, reflecting its specialized use and patent exclusivity.
3. Are there any upcoming regulatory changes affecting pricing?
No major regulatory updates are currently scheduled but watch for indications expansion or new formulary guidelines.
4. What strategies could influence future prices?
Patent expirations, introduction of generics, and formulary restrictions can impact prices.
5. How does antimicrobial resistance impact supply and pricing?
Increased resistance elevates demand, supporting price stability or growth; the opposite can occur if resistance patterns shift or new therapies enter the market.
References
- FDA. (2023). Xerava (eravacycline) [Prescribing Information].
- IQVIA. (2023). National Prescription Audit.
- Centers for Medicare & Medicaid Services. (2023). Drug pricing and reimbursement policies.
- MarketResearch.com. (2023). Antibiotic Market Reports.
- Wharton, J. et al. (2022). Trends in antimicrobial resistance and implications for therapy. Journal of Infectious Diseases, 226(3), 359-369.
